Last synced on 14 November 2025 at 11:06 pm

IVOBASE HYBRID, IVOBASE HIGH IMPACT

Page Type
Cleared 510(K)
510(k) Number
K103391
510(k) Type
Traditional
Applicant
IVOCLAR VIVADENT, INC.
Country
United States
FDA Decision
Substantially Equivalent
Decision Date
2/17/2011
Days to Decision
90 days
Submission Type
Statement

IVOBASE HYBRID, IVOBASE HIGH IMPACT

Page Type
Cleared 510(K)
510(k) Number
K103391
510(k) Type
Traditional
Applicant
IVOCLAR VIVADENT, INC.
Country
United States
FDA Decision
Substantially Equivalent
Decision Date
2/17/2011
Days to Decision
90 days
Submission Type
Statement